Overview

* Akebia Q2 2025 revenue rises to $62.5 mln, beating analyst expectations

* Net income for Q2 2025 beats estimates, reaching $0.2 mln

* Company expands Vafseo prescribing access through dialysis partnerships

Result Drivers

* VAFSEO GROWTH - Prescription demand for Vafseo increased by 55% over Q1 2025, with more than 725 prescribers writing prescriptions

* DIALYSIS PARTNERSHIPS - Akebia is expanding Vafseo access through partnerships with DaVita, DCI, and IRC, expecting protocols to reach over 75,000 patients by end of Q3

* REFILL PRESCRIPTIONS - Over 80% of Vafseo prescriptions in Q2 were refills, with average dose increasing by 25%

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $62.47 $47.20

Revenue mln mln (5

Analysts

)

Q2 EPS -$0.02

(4

Analysts

)

Q2 Net Beat $247,000 -$4.67

Income mln (4

Analysts

)

Q2 Beat $14.09 $2.03

Operatin mln mln (3

g Income Analysts

)

Q2 Basic

EPS

Q2 $38.46

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy."

* Wall Street's median 12-month price target for Akebia Therapeutics Inc ( AKBA ) is $7.00, about 45.9% above its August 6 closing price of $3.79

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)